{"filings":[{"id":678796,"accession_number":"0001551306-26-000109","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-27T13:13:46+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Progyny shareholders approve elimination of supermajority voting requirements","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Super majority amendments passed with >65M votes for, 357K against.","Charter and bylaw amendments effective May 21, 2026, removing supermajority to remove directors and amend bylaws.","All three Class I director nominees elected: Lloyd Dean, Kevin Gordon, Cheryl Scott.","Ratification of Ernst & Young as auditor for FY2026 approved with 71M votes for.","Advisory say-on-pay approved with 61.8M votes for vs 3.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":650877,"accession_number":"0001551306-26-000074","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-26T13:15:09+00:00","items":["8.01"],"status":"ready","headline":"Progyny board approves $200M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $200M of common stock, funded from available cash balances.","Repurchases may be made through open market transactions or Rule 10b5-1 plans.","Program may be suspended or discontinued at any time; no assurance on number or prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93581,"accession_number":"0001551306-26-000062","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q1 rev $328.5M (+1.4%), adj EPS $0.50; guides FY rev $1.365-1.405B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $328.5M (+1.4% YoY); ex-lost client revenue grew 12.2%. Net income $24.2M ($0.29 diluted) vs $15.1M.","Gross margin improved to 25.3% from 23.4%; Adjusted EBITDA $56.6M (17.2% margin) vs $57.8M (17.8%).","Completed $200M buyback; repurchased 8.8M shares total. Board evaluating new program, decision by end of May.","Client count 595 (up 63 YoY); covered lives ~7.2M. ART cycles 15,647 vs 16,160 (transition impact).","FY 2026 guidance: rev $1.365-1.405B, adj EBITDA $232-244M, adj EPS $1.98-2.09. Q2: rev $342-355M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":328504000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105332,"accession_number":"0001551306-26-000040","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Progyny settles derivative suit over director pay; caps annual comp at $288k per director","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Derivative action challenged non-employee director compensation since 2020; settlement includes governance reforms.","New policy caps annual director awards at $48k cash and $240k equity, total $288k per director.","Committee chairs and lead independent director receive additional cash awards ($25k, $20k, $15k, $40k).","Plaintiff's counsel to receive $450,000 in fees/expenses from defendants/insurers, subject to court approval.","Settlement hearing set for May 28, 2026; reforms must be maintained for at least 4 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105331,"accession_number":"0001551306-26-000012","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q4 revenue up 6.7% to $318.4M; guides FY2026 revenue $1.355B-$1.405B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $318.4M (+6.7% YoY); FY2025 revenue $1.2887B (+10% YoY); gross margin expanded to 24.1%.","Q4 net income $12.5M ($0.14 diluted EPS); adj. EPS $0.48; adj. EBITDA $51.4M (16.1% margin).","Full year operating cash flow record $210.2M; repurchased 3.3M shares in Q4, 6.5M total under $200M authorization.","FY2026 revenue guidance $1.355B-$1.405B; adj. EBITDA $224M-$239M; adj. EPS $1.83-$1.95.","Client count 555 as of Dec 2025 (up from 473); expects ~600 clients representing ~7.2M covered lives in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1288661000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105330,"accession_number":"0001551306-26-000009","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny expects Q4 2025 revenue, net income, Adj. EBITDA slightly above prior guidance","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["CEO cites favorable Q4 member engagement vs. November guidance.","Expects Q4 revenue, net income and Adjusted EBITDA slightly above prior ranges.","Update excludes non-cash impacts from departure of President Michael Sturmer.","Presenting at 44th Annual JP Morgan Healthcare Conference on Jan 13, 2026.","No specific revised figures provided; guidance remains qualitative."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":1288661000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121607,"accession_number":"0001551306-25-000218","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Progyny President Michael Sturmer to depart Dec 31, 2025; no successor named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["President Michael Sturmer's employment ends Dec 31, 2025.","No successor named; company cites recent additions of CCO, CTO, COO, CPO.","Sturmer will serve as consultant through Dec 31, 2026 with $250k annual fee.","Vested options extended if consulting continues through June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121606,"accession_number":"0001551306-25-000186","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Progyny Q3 revenue $313.3M (+9.3% YoY), raises FY2025 guidance; board authorizes $200M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $313.3M (+9.3% YoY), net income $13.9M ($0.15 EPS), adj. EBITDA $55.0M (17.5% margin).","New clients: 80+ new, 900k new lives, ~100% retention for 2026.","FY2025 revenue guidance raised to $1.263-1.278B; adj. EBITDA $216-220M.","Board authorized up to $200M share repurchase program.","Record $156M operating cash flow in first nine months of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":970258000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138264,"accession_number":"0001551306-25-000161","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 revenue $332.9M (+9.5% YoY); raises FY2025 guidance on strong member engagement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $332.9M, up 9.5% YoY; ex-large-client transition revenue grew 18%.","Adjusted EBITDA $57.9M (17.4% margin); adjusted EPS $0.48 vs $0.43 prior year.","Raises FY2025 revenue guidance to $1.235B-$1.270B; adjusted EPS guidance to $1.70-$1.78.","Record H1 operating cash flow $105.3M; no debt; entered $200M revolver (undrawn).","Fertility clients grew to 542 from 463 YoY; ART cycles 16,938 (+8.8% YoY)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":656912000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138263,"accession_number":"0001551306-25-000153","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Progyny enters $200M credit facility; Q2 results expected slightly above guidance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $200M revolving credit facility maturing July 1, 2030; undrawn at closing.","Facility secured by substantially all assets; variable interest based on SOFR or base rate plus margin.","Q2 2025 revenue, Adjusted net income, and Adjusted EBITDA expected slightly above prior guidance.","Company has no planned use for facility; capital priorities (buybacks, product expansion, acquisitions) unchanged.","JPMorgan Chase Bank acts as administrative agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155718,"accession_number":"0001551306-25-000131","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny shareholders reject advisory vote on executive compensation at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director nominees Norman Payson, Debra Morris, Elizabeth Bierbower elected with majority votes.","Ratification of Ernst & Young as independent auditor approved (75.2M for, 544k against).","Advisory say-on-pay proposal failed: 43.9M against vs 24.4M for; 7.3M broker non-votes.","88.4% of outstanding shares (75.7M) represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155717,"accession_number":"0001551306-25-000092","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue $324M (+16.5% YoY), raises FY2025 guidance above prior outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $324.0M (+16.5% YoY); gross margin 23.4% vs 22.4% a year ago.","Adjusted EBITDA $57.8M (17.8% margin) vs $50.3M (18.1% margin) in Q1 2024.","Net income $15.1M ($0.17 EPS); adjusted EPS $0.48 vs $0.39 in prior year.","FY2025 revenue guidance raised to $1.185B-$1.235B; adjusted EBITDA guided $190M-$203M.","Fertility clients 532 (up from 451); ART cycles 16,160 (+9.2% YoY). Large client transition contributed $31.3M revenue in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":324038000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155716,"accession_number":"0001551306-25-000070","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dr. Fred E. Cohen to leave Progyny board after 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Cohen notified Progyny on April 9, 2025 of his decision not to stand for reelection at the 2025 Annual Meeting.","Decision unrelated to any disagreement with the Company on operations, policies, or practices.","Cohen will continue serving as director through the end of his current term at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174208,"accession_number":"0001551306-25-000025","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K/A","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reports Q4 revenue $298.4M (+10.6% YoY); FY2025 guidance $1.175-1.225B; corrects 2025 ART cycle outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 EPS); Adj. EBITDA $47.5M (15.9% margin).","FY2024 revenue $1.167B (+7.2%); net income $54.3M ($0.57 EPS); Adj. EBITDA $198.8M (17.0% margin).","FY2025 guidance: revenue $1.175-1.225B; Adj. EBITDA $188-201M; Adj. EPS $1.52-1.62.","Correction: 2025 ART cycle guidance revised to 61,600-64,300 from 59,350-61,850; no change to financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167221000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174211,"accession_number":"0001551306-25-000022","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q4 rev $298.4M (+10.6%); large client non-renewal pressures 2025 guide of 1-5% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $298.4M (+10.6% YoY); net income $10.5M ($0.12 diluted EPS) vs $13.5M ($0.13) prior year.","Adjusted Q4 EPS $0.42 vs $0.32 prior year; Adjusted EBITDA $47.5M (+10%).","Full year 2024 revenue $1,167.2M (+7.2%); net income $54.3M ($0.57) vs $62.0M ($0.62).","One large client did not renew for 2025; excluding it, 2024 revenue grew 8.5%; expects >530 clients in 2025.","FY2025 guidance: revenue $1.175B-$1.225B (1-5% growth), adjusted EBITDA $188M-$201M, adjusted EPS $1.52-$1.62."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":1167221000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174210,"accession_number":"0001551306-25-000010","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Progyny appoints Debra Morris to board effective Jan 16, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Debra Morris appointed as Class III director, term expires at 2025 annual meeting.","Morris will serve on Compensation Committee and receives $40k annual cash retainer.","Initial grant of options to purchase 44,000 shares vesting over four years.","Morris is President of AccessHope, former CFO of Apria; also on boards of REXR and BTMD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174209,"accession_number":"0001551306-25-000006","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny expects Q4 2024 revenue, net income, Adjusted EBITDA slightly above prior guidance","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company updates guidance at JPM Healthcare Conference; Q4 results expected slightly above November ranges.","Previous guidance assumed member activity flat to down vs Q3 2024; improved pacing drove the beat.","CEO Pete Anevski to present on Jan 14, 2025 at 7:30 a.m. PT; audiocast available on investor site.","No specific dollar amounts or revised ranges provided in the press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191141,"accession_number":"0001551306-24-000199","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q3 revenue up 2% to $286.6M, net income falls 34% to $10.4M; cuts FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $286.6M (+2% YoY); net income $10.4M ($0.11 diluted EPS) vs $15.9M ($0.16) in Q3 2023.","Adjusted EBITDA $46.5M (-7.1% YoY); margin 16.2% vs 17.8% a year ago.","Full-year 2024 revenue guidance lowered to $1.135-1.150B; adjusted EBITDA guidance $189-194M.","New sales season adds 80+ clients, 1.1M new covered lives; also selected by two health plans as preferred partner.","Q3 utilization rate lower than expected; members took longer to progress, consuming fewer treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":868790000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207620,"accession_number":"0001551306-24-000183","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Progyny loses client representing ~12-13% of revenue; termination effective Jan 1, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Client with ~670k members exercised 90-day termination option; no disputes or service issues cited.","Client comprised 12% of H1 2024 revenue and 13% of FY 2023 revenue; no other client > single-digit percentage.","No adverse impact expected on FY 2024 financial results; services continue through end of 2024.","Company expects overall member count to increase in 2025 despite the loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207619,"accession_number":"0001551306-24-000163","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Progyny holds inaugural Investor Day; presentation furnished without new financial data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Hosted first-ever Investor Day on August 12, 2024; webcast replay available on website.","Exhibit 99.1 contains only title slides and safe harbor language; no specific financial targets or operational metrics disclosed in filing.","No changes to guidance, dividend, or executive leadership announced in the 8-K or exhibit.","Event is procedural; material content, if any, would be in the full presentation not fully included in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207618,"accession_number":"0001551306-24-000152","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q2 beats on adjusted EBITDA but cuts full-year guidance on lower revenue per member","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $304.1M (+8.8% YoY), record Adj. EBITDA $54.5M (+15% YoY), margin 17.9%.","Net income $16.5M ($0.17 diluted EPS); Adj. EPS $0.43 vs $0.36 a year ago.","Board authorized $100M stock buyback; 6.8M shares repurchased YTD under prior programs.","Full-year 2024 revenue guidance revised to $1.165-1.20B (7-10% growth); Adj. EBITDA $199-209M.","Q3 2024 revenue guidance $290-303M; Adj. EBITDA $47.5-51.0M; citing lower revenue per utilizing member."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":582165000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225071,"accession_number":"0001551306-24-000128","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Progyny stockholders re-elect directors, ratify EY, approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected directors Anevski, Holstein, Park, Schlanger with 62M+ votes for each; broker non-votes 5,878,612.","Ratified Ernst & Young as independent auditor for fiscal 2024: 89.5M for, 331K against, 163K abstentions.","Advisory say-on-pay approved: 82.1M for, 1.9M against, 134.5K abstentions.","Turnout: 90,037,222 shares (93.68% of eligible) voted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225070,"accession_number":"0001551306-24-000107","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Progyny board authorizes $100M share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved a new $100M share repurchase program on May 22, 2024.","Follows an earlier program announced Feb 29, 2024; funded from available cash.","Repurchases may be via open market or 10b5-1 plans; program can be suspended anytime.","No assurances on number of shares or prices at which purchases will be made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225069,"accession_number":"0001551306-24-000096","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny Q1 revenue up 7.6% to $278M; cuts FY revenue guidance to $1.23-1.27B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $278.1M (+7.6% YoY), net income $16.9M ($0.17 diluted EPS), adjusted EPS $0.39.","Adjusted EBITDA $50.3M (+8%), margin 18.1% vs 17.9% prior year period.","FY 2024 revenue guidance lowered to $1.23-1.27B (from prior $1.27-1.31B) citing lower March utilization.","Repurchased 723,577 shares for $26.4M in Q1; $32M remains under $100M buyback authorization.","Clients grew 19% YoY to 451; ART cycles increased 12.4% to 14,802."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":278078000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244294,"accession_number":"0001551306-24-000018","cik":1551306,"company_name":"Progyny, Inc.","ticker":"PGNY","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Progyny reports record FY23 revenue $1.09B (+38%); guides FY24 $1.285-$1.315B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 revenue $1,088.6M (+38% YoY); net income $62.0M ($0.62 diluted EPS), adj. EBITDA $187.1M (+49%).","Q4 revenue $269.9M (+26%); net income $13.5M ($0.13 EPS); adj. EBITDA $43.2M (+31%).","Clients grew to 392 as of Dec 31, 2023, from 288 a year earlier; expects >460 clients in 2024.","FY24 revenue guidance $1.285-$1.315B (+18-21%), adj. EBITDA $224-$232M, adj. EPS $1.54-$1.59.","Q1 2024 revenue guided $285-$292M (+10-13%); cites ~$15M headwind from short-term treatment mix shift."],"consensus_eps_estimate":null,"consensus_eps_actual":0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1088598000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2004885563.0910676,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}